Back to search results

Guselkumab for Psoriatic Arthritis and Fatty Liver Disease

This study is looking into how the medication guselkumab affects liver problems in people with psoriatic arthritis (PsA). PsA is a type of arthritis that affects some people with psoriasis, causing joint pain and swelling. Many people with PsA also have nonalcoholic fatty liver disease (NAFLD), and this study wants to understand why. Researchers will follow 20 adults with PsA who also have NAFLD and active PsA symptoms, such as swollen joints or skin plaques. You would have two visits over 24 weeks. The main goal is to see if guselkumab changes the severity of your NAFLD after 24 weeks. The study is also exploring shared causes between PsA and NAFLD.

Study design
This is an interventional study planning to enroll 20 participants. It is a longitudinal study, meaning participants are followed over a period of time.
What's involved
You would have two visits over a 24-week period. The study involves assessing the impact of biological therapies on liver disorders, joints, and skin.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for measuring changes in NAFLD severity is at 24 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06586281

Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy

Recruiting
NAAll AgesInterventionalBasic science
University of California, San Diego
~20 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:Guselkumab

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in NAFLD severity
Measured over 24 weeks

Conditions

Psoriatic Arthritis

Explore related trials

Psoriatic Arthritis

Where it's being run

1 sites across 1 states
California1

Who to contact

Monica Guma
[email protected]
8588226523
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Hepatitis B as defined as presence of hepatitis B surface antigen (HBsAg).
Previous or current infection with Hepatitis C as defined by presence of hepatitis C virus Abin serum (anti-HCV Ab).
Autoimmune hepatitis as defined by anti-nuclear antibody (ANA) of 1:160 or greater and liver histology consistent with autoimmune hepatitis or previous response to immunosuppressive therapy.
Autoimmune cholestatic liver disorders as defined by elevation of alkaline phosphatase and anti-mitochondrial antibody of greater than 1:80 or liver histology consistent with primary biliary cirrhosis or elevation of alkaline phosphatase and liver histology consistent with sclerosing cholangitis.
Wilson disease as defined by ceruloplasmin below the limits of normal and liver histology consistent with Wilson disease.
Alpha-1-antitrypsin deficiency as defined by alpha-1-antitrypsin level less than normal and liver histology consistent with alpha-1-antitrypsin deficiency.
Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy and homozygosity for C282Y or compound heterozygosity for C282Y/H63D.
Drug-induced liver disease as defined on the basis of typical exposure and history.
Bile duct obstruction as shown by imaging studies.
History of gastrointestinal bypass surgery or ingestion of medications known to produce steatosis, such as corticosteroids, high-dose estrogen, tamoxifen, amiodarone or tetracycline in the previous 6 months.
Evidence of cirrhosis or previously known cirrhosis based on the results from previous liver biopsy or history of portal hypertension presented by ascites, hepatic encephalopathy or varices
Presence of regular and/or excessive use of alcohol (defined as \>30g/day for males and \>15g/day for females) for a period longer than 2 years at any times in the last 10 years
Serum creatinine \> 2.0 mg/dL
The subject is a pregnant or nursing female or is planning to become pregnant
Life expectancy less than 5 years 3. History of known HIV infection

What this trial measures

  • Change in NAFLD severity24 weeks

    Defined by MRI-PDFF responders (relative change in liver fat ≥30%) vs non-responders (relative change in liver fat \<30%) at Week 24.